

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
December 18, 2019

**MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Lauren Tesh Hotaki, PharmD, BCPS, BCIDP**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Massimo Cristofanilli, MD, FACP**

Associate Director of Translational Research and  
Precision Medicine  
Robert H. Lurie Comprehensive Cancer Center  
Chicago, Illinois

**Susan Halabi, PhD**

Professor of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, North Carolina

**Christian S. Hinrichs, MD**

Investigator & Lasker Clinical Research Scholar  
Experimental Transplantation and Immunology  
Branch  
National Cancer Institute  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Philip Hoffman, MD**

*(Chairperson)*  
Professor of Medicine  
The University of Chicago  
Section of Hematology/Oncology  
Department of Medicine  
Chicago, Illinois

**Heidi D. Klepin, MD, MS**

Associate Professor of Internal Medicine  
Section of Hematology and Oncology  
Wake Forest University Health Sciences  
Winston Salem, North Carolina

**Anthony D. Sung, MD**

Assistant Professor of Medicine  
Duke University School of Medicine  
Duke Adult Blood and Marrow Transplant Clinic  
Durham, North Carolina

**Thomas S. Uldrick, MD, MS**

Deputy Head, Global Oncology  
Associate Member, Vaccine and Infectious Disease  
Division  
Associate Member, Clinical Research Division  
Fred Hutchinson Cancer Research Center  
Seattle, Washington

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
December 18, 2019

**MEETING ROSTER (cont.)**

---

---

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)**

**Jonathan D. Cheng, MD**

*(Industry Representative)*  
Vice President and Oncology Therapeutic Area  
Head Merck Research Laboratories, Oncology  
Clinical Research  
North Wales, Pennsylvania

**TEMPORARY MEMBERS (Voting)**

**Randy W. Hawkins, MD**

*(Acting Consumer Representative)*  
Department of Internal Medicine  
Internal Medicine/Pulmonary & Critical Care  
Charles R. Drew University of Medicine and  
Science  
Los Angeles, California

**Christian F. Meyer, MD, MS, PhD**

Clinical Associate and Assistant Professor of Adult  
Sarcomas, Medical Oncology  
Johns Hopkins Hospital  
Baltimore, Maryland

**Richard F. Riedel, MD**

Associate Professor of Medicine (with Tenure)  
Associate Director, Duke Sarcoma Program  
Duke Cancer Institute  
Duke University Health System  
Durham, North Carolina

**Kimberly A. Webb, MA**

*(Patient Representative)*  
Huntington Beach, California

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE),  
FDA  
Acting Director, Office of Oncologic Disease  
(OOD)  
Office of New Drugs (OND), CDER, FDA

**Marc Theoret, MD**

Acting Deputy Director  
OOD, OND, CDER, FDA  
Acting Associate Director for Immunotherapeutics  
OCE, FDA

**Steven Lemery, MD**

Acting Director  
Division of Oncology 3 (DO3)  
OOD, OND, CDER, FDA

**Ashley Ward, MD**

Clinical Team Leader  
Melanoma/Sarcoma Team  
DO3, OOD, OND, CDER, FDA

**Leslie Doros, MD**

Clinical Reviewer  
Melanoma/Sarcoma Team  
DO3, OOD, OND, CDER, FDA